TEP With 68-DOTANOC in Gastroenteropancreatic Neuroendocrine Tumors
NCT ID: NCT01747096
Last Updated: 2022-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
130 participants
INTERVENTIONAL
2012-11-30
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Therapeutic impact and safety of PET / CT with 68Ga-DOTANOC will also be assessed. Expected results are a confirmation of the superiority of 68Ga-PET DOTANOC versus scintigraphy octreoscan ®, with a potential impact on the therapeutic management of patients.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
[68 Ga]-DOTANOC PET/CT in GEP-NETs
NCT02608203
Whole Body Dynamic 68Ga-DOTATOC PET/CT in Neuroendocrine Tumors
NCT03576040
Explore the Clinical Value of 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in Neuroendocrine Neoplasms
NCT03288597
A Prospective, Open-label Study of [68Ga]Ga-DOTA-TATE in Patients With Neuroendocrine Neoplasms (NENs) and Healthy Volunteers in Japan
NCT06240741
68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)
NCT02174679
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
68-Ga-DOTANOC
68-Ga-DOTANOC
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
68-Ga-DOTANOC
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* effective contraception or exclusion of pregnancy dosage of beta-HCG in women of childbearing age
* Fortuitous discovery of suggestive tumors of TE-GEP with well documented conventional imaging (multiphase CT; MRI, US endoscopy) associated or not associated with clinical or biological signs of TE-GEP tumors (increase in tumor markers) OR
* Histologically proven GEP-TE (WHO classification 2010 (26) well differentiated in the initial staging OR
* Suspicion of recurrence or progression of well differentiated TE-GEP tumors on conventional imaging or laboratory tests (increase in tumor markers) OR
* Clinical or biological syndrome strongly suggestive of digestive endocrine disease without identification of lesions with conventional imaging
* Informed consent and patient's written
* Affiliation to an insurance
Exclusion Criteria
* TE GEP tumor not differentiated
* Pregnancy and lactation
* Persons protected by law
* Restlessness, inability to lie still hold at least 1 hour; Claustrophobia
* Poor compliance predictable or inability to undergo medical test for geographical, social or psychological
* Treatment with radiotherapy, chemotherapy or other antitumor treatment within 6 weeks of previous morphological and scintigraphic examinations. In case of treatment with somatostatin analogues delayed, scans will be performed 4 weeks after the last injection. However, a shorter period may be observed to avoid to do again the initial assessment exams.
* malignancy except basal cell cancers and cancer in situ of the cervix
* Contraindication of injection of a contrast agent necessary for the production of multiphase scanner.
* Patients who had a CT scan without injection of contrast material can not participate in the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nantes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Catherine Ansquer, MD
Role: PRINCIPAL_INVESTIGATOR
Nantes Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Angers Hospital
Angers, , France
Hôpital Beaujon
Clichy, , France
Hôpital Bichat
Paris, , France
Institut de Cancérologie de l'Ouest, René Gauducheau
Saint-Herblain, , France
Nantes Hospital
Saint-Herblain, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BRD/11/05-K
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.